Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

345 ARTÍCULOS , VIENDO DEL 151 AL 165

Potential repurposing of oncology drugs for the treatment of Alzheimer's disease

Araki W.

BMC Med. 2013 Mar 26;11:82. doi: 10.1186/1741-7015-11-82.

Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT)

Alzheimer's Disease Anti-inflammatory Prevention Trial Research Group.

Alzheimers Dement. 2013 Nov;9(6):714-23. doi: 10.1016/j.jalz.2012.11.012. Epub 2013 Apr 3.

Innate immunity in Alzheimer's disease: a complex affair

Guillot-Sestier MV, Town T.

CNS Neurol Disord Drug Targets. 2013 Aug;12(5):593-607. doi: 10.2174/1871527311312050008.

Aluminum in the central nervous system (CNS): toxicity in humans and animals, vaccine adjuvants, and autoimmunity

Shaw CA, Tomljenovic L.

Immunol Res. 2013 Jul;56(2-3):304-16. doi: 10.1007/s12026-013-8403-1.

Prolonged running, not fluoxetine treatment, increases neurogenesis, but does not alter neuropathology, in the 3xTg mouse model of Alzheimer's disease

Marlatt MW, Potter MC, Bayer TA, van Praag H, Lucassen PJ.

Curr Top Behav Neurosci. 2013;15:313-40. doi: 10.1007/7854_2012_237.

Bed bugs reproductive life cycle in the clothes of a patient suffering from Alzheimer's disease results in iron deficiency anemia

Sabou M, Imperiale DG, Andrès E, Abou-Bacar A, Foeglé J, Lavigne T, Kaltenbach G, Candolfi E.

Parasite. 2013;20:16. doi: 10.1051/parasite/2013018. Epub 2013 May 15.

The neglected role of histamine in Alzheimer's disease

Naddafi F, Mirshafiey A.

Am J Alzheimers Dis Other Demen. 2013 Jun;28(4):327-36. doi: 10.1177/1533317513488925. Epub 2013 May 15.

Epigenetic mechanisms in Alzheimer's disease: implications for pathogenesis and therapy

Wang J, Yu JT, Tan MS, Jiang T, Tan L.

Ageing Res Rev. 2013 Sep;12(4):1024-41. doi: 10.1016/j.arr.2013.05.003. Epub 2013 May 17.

The role of Beta-adrenergic receptor blockers in Alzheimer's disease: potential genetic and cellular signaling mechanisms

Lương Kv, Nguyen LT.

Am J Alzheimers Dis Other Demen. 2013 Aug;28(5):427-39. doi: 10.1177/1533317513488924. Epub 2013 May 20.

Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment

Douaud G, Refsum H, de Jager CA, Jacoby R, Nichols TE, Smith SM, Smith AD.

Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9523-8. doi: 10.1073/pnas.1301816110. Epub 2013 May 20.

Do angiotensin receptor blockers prevent Alzheimer's disease?

Hajjar I, Rodgers K.

Curr Opin Cardiol. 2013 Jul;28(4):417-25. doi: 10.1097/HCO.0b013e3283620745.

Amyloid β precursor protein as a molecular target for amyloid β--induced neuronal degeneration in Alzheimer's disease

Bignante EA, Heredia F, Morfini G, Lorenzo A.

Neurobiol Aging. 2013 Nov;34(11):2525-37. doi: 10.1016/j.neurobiolaging.2013.04.021. Epub 2013 May 25.

[Research progress of transgenic Drosophila model of Alzheimer disease]

Tan Y, Ji YB, Zhao J.

Yao Xue Xue Bao. 2013 Mar;48(3):333-6.

Window of opportunity for estrogen and progestin intervention in brain aging and Alzheimer's disease

Singh M, Simpkins JW, Simpkins JW, Bimonte-Nelson HA, Bimonte-Nelson HA, Brinton RD, Brinton RD.

Brain Res. 2013 Jun 13;1514:1-2. doi: 10.1016/j.brainres.2013.04.044.

Cerebrovascular contributions to Alzheimer's disease pathophysiology and potential therapeutic interventions in mouse models

Thomason LA, Stefanovic B, McLaurin J.

Eur J Neurosci. 2013 Jun;37(12):1994-2004. doi: 10.1111/ejn.12181.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias